Featured on BioCentury: Phase I start marks first for anti-SARS-CoV-2 mAbs, first for AbCellera

“A COVIDcampaign-pages/bispecifics/-19 mAb from Eli Lilly and AbCellera has become the first against the virus to start human trials and is also the Vancouver-based company’s first product to enter the clinic. While the Phase I study of Ly-CoV555 is assessing safety, its evaluation in hospitalized COVIDcampaign-pages/bispecifics/-19 patients leaves room for exploratory observations that may hint at efficacy.”

Read full coverage on BioCentury.


Together we can make game-changing discoveries.